NCT05600634

Brief Summary

The purpose of this study was to explore the accuracy of sentinel skin grafts from the same donor source in diagnosing renal allograft rejection, and to provide new ideas and options for the later clinical diagnosis of renal allograft rejection. Further, try to provide timing guidance for early immunization intervention.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for all trials

Timeline
8mo left

Started Jan 2024

Typical duration for all trials

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress78%
Jan 2024Dec 2026

First Submitted

Initial submission to the registry

October 27, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 31, 2022

Completed
1.2 years until next milestone

Study Start

First participant enrolled

January 1, 2024

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

November 28, 2023

Status Verified

October 1, 2023

Enrollment Period

2.5 years

First QC Date

October 27, 2022

Last Update Submit

November 27, 2023

Conditions

Outcome Measures

Primary Outcomes (3)

  • 2017 Banff Kidney Transplantation Rejection Rating

    A rating evaluation on kidney rejection

    Through study completion, an average of 1 year

  • 2007-edition Banff skin containing allogeneic composite histopathological diagnosis grading

    Skin histopathological diagnosis

    Through study completion, an average of 1 year

  • Renal function testing

    Blood Cr and Bun testing

    Through study completion, an average of 1 year

Secondary Outcomes (2)

  • Renal ultrasound diagnosis

    Through study completion, an average of 1 year

  • Complications

    Through study completion, an average of 1 year

Study Arms (1)

Kidney and skin transplataiton

Procedure: Skin allotransplantation

Interventions

Sentinel skin grafts from the same donor source will be carried on in the meantime of kidney transplantation for assisting to detect acute renal rejection.

Kidney and skin transplataiton

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

This study is an exploratory study. In the early stage, there is no relevant study on the accuracy of sentinel skin flap monitoring renal rejection, and there is a lack of corresponding sensitivity and specificity indicators. Considering that the incidence of acute rejection in the first year after transplantation is 15-30%, it is estimated that 20 cases will be included. Because the experimental data may be lost, or the participants may withdraw from the trial or lose the interview, the sample size will be increased by 20%, and finally 24 cases will be included in the trial.

You may qualify if:

  • Patients with end-stage renal disease undergoing renal transplantation;
  • years old;
  • Postoperative follow-up points are complete (visit the hospital every week in the first month after surgery, every two weeks in 2-3 months, every four to six months, and every three months in 7-12 months. Follow up at any time when skin rejection is observed. The follow-up time may be adjusted when the condition changes);
  • The participants had good compliance, volunteered to participate in the test and signed the informed consent form.

You may not qualify if:

  • Untreated or disseminated malignant tumor;
  • Active period of infectious diseases;
  • Serious cardiovascular disease occurred recently;
  • Combined with other important organ failure;
  • History of mental illness or cognitive impairment;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Xijing Hospital, Ari Force Medical University

Xi'an, Shannxi, 400041, China

RECRUITING

First Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310000, China

RECRUITING

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310000, China

RECRUITING

Central Study Contacts

Chenggang Yi, M.D.

CONTACT

Songxue Guo, M.D.

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 27, 2022

First Posted

October 31, 2022

Study Start

January 1, 2024

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

November 28, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will not share

Locations